お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は先天性心疾患市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは先天性心疾患の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の先天性心疾患市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは先天性心疾患のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に先天性心疾患市場を分類しています。本研究に含まれる主な企業は：Pfizer、Abbott Laboratories、Eli Lilly、Ranbaxy Pharmaceutical

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Hypoplasia
    Obstructive
    Septal Defects

用途別の市場セグメント：
    Hospitals
    Ambulatory Surgical Centers
    Diagnostic Centers
    Others

本レポートの詳細内容
世界の先天性心疾患市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、先天性心疾患タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の先天性心疾患収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の先天性心疾患市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、先天性心疾患市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

先天性心疾患のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：先天性心疾患のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：先天性心疾患の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章先天性心疾患企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：先天性心疾患の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：先天性心疾患の主要企業の概要を提供し、製品の説明と仕様、先天性心疾患の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Congenital diseases are disorders in a newborn due to certain genetic factors (and sometimes in association with the environment) that often results in malformations or underdeveloped organs. Congenital Heart Diseases (CHD) results in malformed or undeveloped heart that presents in a newborn with breathing and circulation disorders. According to Lancet medical journal, CHD caused death of 0.22 million individuals and newborns globally in the year 2010. CHD was earlier erroneously associated with premature births, the association has no direct correlation with all forms of CHD and is mainly one of the many factors that can cause it. The genetic factors causing CHD consist of chromosomal errors in fertilization and the following meiotic division, these include: large chromosomal defects in trisomal chromosomes; small chromosomal defects like microdeletion of long/short arm of chromosome and random/environmentally induced mutation of heart muscle cell proteins, or associated proteins etc. The environmental factors like rubella infections, thalidomide drugs, metals (lithium, lead, mercury, etc), chronic illness in the mother (systemic lupus, diabetes, phenylketonuria, etc). Embryological changes, hormonal changes in the mother and certain birth deficiencies can also cause CHD and other birth defects in children. Besides these, according to some medical research reports, maternal obesity increased the chances of CHD in newborns; obesity was shown to increase the risk of previously hidden genetic traits of CHD in the new born children of such obese mothers.
Market Analysis and Insights: Global Congenital Heart Diseases Market
The global Congenital Heart Diseases market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The treatment of CHD varies from case to case; genetic testing/screening is mandatory in case the doctor suspects a genetic cause for the disease, in developed countries this is done for all newborns. The next step would be surgery or drug treatment, again this depends upon the severity of the condition. In most cases CHD presents itself as serious conditions with high risk of complications, hence surgery is the most followed procedure. In certain disorders like ASD a pediatric surgeon may ask the parents of a CHD child to wait for the child’s growth as ASD is known to disappear gradually, a surgery is performed if ASD persists after the child’s growth. Certain cases also require multiple surgeries and stenting in order to restore a malformed tract in the lungs, etc. Drugs like diuretics are given to regulate vasoconstriction that alleviates deoxygenation and helps remove toxins from the body, besides reducing the heartbeat.
Report Covers:
This report presents an overview of global market for Congenital Heart Diseases market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Congenital Heart Diseases, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Congenital Heart Diseases, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Congenital Heart Diseases revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Congenital Heart Diseases market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Congenital Heart Diseases revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Abbott Laboratories, Eli Lilly and Ranbaxy Pharmaceutical, etc.

Market Segmentation
By Company
    Pfizer
    Abbott Laboratories
    Eli Lilly
    Ranbaxy Pharmaceutical

Segment by Type
    Hypoplasia
    Obstructive
    Septal Defects

Segment by Application
    Hospitals
    Ambulatory Surgical Centers
    Diagnostic Centers
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Congenital Heart Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Congenital Heart Diseases companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Congenital Heart Diseases revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Congenital Heart Diseases Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Hypoplasia
    Table 3. Key Players of Obstructive
    Table 4. Key Players of Septal Defects
    Table 5. Global Congenital Heart Diseases Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Congenital Heart Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Congenital Heart Diseases Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Congenital Heart Diseases Market Share by Region (2019-2024)
    Table 9. Global Congenital Heart Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Congenital Heart Diseases Market Share by Region (2025-2030)
    Table 11. Congenital Heart Diseases Market Trends
    Table 12. Congenital Heart Diseases Market Drivers
    Table 13. Congenital Heart Diseases Market Challenges
    Table 14. Congenital Heart Diseases Market Restraints
    Table 15. Global Congenital Heart Diseases Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Congenital Heart Diseases Revenue Share by Players (2019-2024)
    Table 17. Global Top Congenital Heart Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Congenital Heart Diseases as of 2023)
    Table 18. Global Congenital Heart Diseases Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Congenital Heart Diseases Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Congenital Heart Diseases, Headquarters and Area Served
    Table 21. Global Key Players of Congenital Heart Diseases, Product and Application
    Table 22. Global Key Players of Congenital Heart Diseases, Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Congenital Heart Diseases Revenue Market Share by Type (2019-2024)
    Table 26. Global Congenital Heart Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Congenital Heart Diseases Revenue Market Share by Type (2025-2030)
    Table 28. Global Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Congenital Heart Diseases Revenue Share by Application (2019-2024)
    Table 30. Global Congenital Heart Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Congenital Heart Diseases Revenue Share by Application (2025-2030)
    Table 32. North America Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Congenital Heart Diseases Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Congenital Heart Diseases Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Congenital Heart Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Congenital Heart Diseases Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Congenital Heart Diseases Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Congenital Heart Diseases Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Congenital Heart Diseases Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Congenital Heart Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Congenital Heart Diseases Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Congenital Heart Diseases Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Congenital Heart Diseases Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Congenital Heart Diseases Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Congenital Heart Diseases Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Congenital Heart Diseases Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Congenital Heart Diseases Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Congenital Heart Diseases Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Congenital Heart Diseases Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Congenital Heart Diseases Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Pfizer Company Details
    Table 65. Pfizer Business Overview
    Table 66. Pfizer Congenital Heart Diseases Product
    Table 67. Pfizer Revenue in Congenital Heart Diseases Business (2019-2024) & (US$ Million)
    Table 68. Pfizer Recent Developments
    Table 69. Abbott Laboratories Company Details
    Table 70. Abbott Laboratories Business Overview
    Table 71. Abbott Laboratories Congenital Heart Diseases Product
    Table 72. Abbott Laboratories Revenue in Congenital Heart Diseases Business (2019-2024) & (US$ Million)
    Table 73. Abbott Laboratories Recent Developments
    Table 74. Eli Lilly Company Details
    Table 75. Eli Lilly Business Overview
    Table 76. Eli Lilly Congenital Heart Diseases Product
    Table 77. Eli Lilly Revenue in Congenital Heart Diseases Business (2019-2024) & (US$ Million)
    Table 78. Eli Lilly Recent Developments
    Table 79. Ranbaxy Pharmaceutical Company Details
    Table 80. Ranbaxy Pharmaceutical Business Overview
    Table 81. Ranbaxy Pharmaceutical Congenital Heart Diseases Product
    Table 82. Ranbaxy Pharmaceutical Revenue in Congenital Heart Diseases Business (2019-2024) & (US$ Million)
    Table 83. Ranbaxy Pharmaceutical Recent Developments
    Table 84. Research Programs/Design for This Report
    Table 85. Key Data Information from Secondary Sources
    Table 86. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Congenital Heart Diseases Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Congenital Heart Diseases Market Share by Type: 2023 VS 2030
    Figure 3. Hypoplasia Features
    Figure 4. Obstructive Features
    Figure 5. Septal Defects Features
    Figure 6. Global Congenital Heart Diseases Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Congenital Heart Diseases Market Share by Application: 2023 VS 2030
    Figure 8. Hospitals Case Studies
    Figure 9. Ambulatory Surgical Centers Case Studies
    Figure 10. Diagnostic Centers Case Studies
    Figure 11. Others Case Studies
    Figure 12. Congenital Heart Diseases Report Years Considered
    Figure 13. Global Congenital Heart Diseases Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Congenital Heart Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Congenital Heart Diseases Market Share by Region: 2023 VS 2030
    Figure 16. Global Congenital Heart Diseases Market Share by Players in 2023
    Figure 17. Global Top Congenital Heart Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Congenital Heart Diseases as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Congenital Heart Diseases Revenue in 2023
    Figure 19. North America Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Congenital Heart Diseases Market Share by Type (2019-2030)
    Figure 21. North America Congenital Heart Diseases Market Share by Application (2019-2030)
    Figure 22. North America Congenital Heart Diseases Market Share by Country (2019-2030)
    Figure 23. United States Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Canada Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Congenital Heart Diseases Market Size YoY (2019-2030) & (US$ Million)
    Figure 26. Europe Congenital Heart Diseases Market Share by Type (2019-2030)
    Figure 27. Europe Congenital Heart Diseases Market Share by Application (2019-2030)
    Figure 28. Europe Congenital Heart Diseases Market Share by Country (2019-2030)
    Figure 29. Germany Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. France Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. U.K. Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Italy Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Russia Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Nordic Countries Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. China Congenital Heart Diseases Market Size YoY (2019-2030) & (US$ Million)
    Figure 36. China Congenital Heart Diseases Market Share by Type (2019-2030)
    Figure 37. China Congenital Heart Diseases Market Share by Application (2019-2030)
    Figure 38. Asia Congenital Heart Diseases Market Size YoY (2019-2030) & (US$ Million)
    Figure 39. Asia Congenital Heart Diseases Market Share by Type (2019-2030)
    Figure 40. Asia Congenital Heart Diseases Market Share by Application (2019-2030)
    Figure 41. Asia Congenital Heart Diseases Market Share by Region (2019-2030)
    Figure 42. Japan Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. South Korea Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. China Taiwan Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. India Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Australia Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Congenital Heart Diseases Market Size YoY (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Congenital Heart Diseases Market Share by Type (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Congenital Heart Diseases Market Share by Application (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Congenital Heart Diseases Market Share by Country (2019-2030)
    Figure 52. Brazil Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Mexico Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Turkey Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Saudi Arabia Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Israel Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. GCC Countries Congenital Heart Diseases Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Pfizer Revenue Growth Rate in Congenital Heart Diseases Business (2019-2024)
    Figure 59. Abbott Laboratories Revenue Growth Rate in Congenital Heart Diseases Business (2019-2024)
    Figure 60. Eli Lilly Revenue Growth Rate in Congenital Heart Diseases Business (2019-2024)
    Figure 61. Ranbaxy Pharmaceutical Revenue Growth Rate in Congenital Heart Diseases Business (2019-2024)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed